Cesium carbonate → tert-butyl (3R)-3-[[5-(5-carbamoyl-1,3-benzothiazol-2-yl)-6-methoxy-2-(morpholin-4-yl)pyrimidin-4-yl]amino]piperidine-1-carboxylate
Reaction equation
[S:1]1[C:5]2[CH:6]=[CH:7][C:8]([C:10]([NH2:12])=[O:11])=[CH:9][C:4]=2[N:3]=[CH:2]1.I[C:14]1[C:15]([NH:28][C@@H:29]2[CH2:34][CH2:33][CH2:32][N:31]([C:35]([O:37][C:38]([CH3:41])([CH3:40])[CH3:39])=[O:36])[CH2:30]2)=[N:16][C:17]([N:22]2[CH2:27][CH2:26][O:25][CH2:24][CH2:23]2)=[N:18][C:19]=1[O:20][CH3:21].C(=O)([O-])[O-].[Cs+].[Cs+]>CN(C=O)C.C1C=CC([P]([Pd]([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)[P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)=CC=1.[Cu](I)I>[C:10]([C:8]1[CH:7]=[CH:6][C:5]2[S:1][C:2]([C:14]3[C:15]([NH:28][C@@H:29]4[CH2:34][CH2:33][CH2:32][N:31]([C:35]([O:37][C:38]([CH3:41])([CH3:40])[CH3:39])=[O:36])[CH2:30]4)=[N:16][C:17]([N:22]4[CH2:23][CH2:24][O:25][CH2:26][CH2:27]4)=[N:18][C:19]=3[O:20][CH3:21])=[N:3][C:4]=2[CH:9]=1)(=[O:11])[NH2:12]Participants
7
Reactant 3
Product 1
Reagents, catalysts & solvents 3
Procedure
Following the same procedure as in step 3 of Example 337 using 1,3-benzothiazole-5-carboxamide (60.6 mg, 0.34 mmol, 1.80 equiv), tert-butyl (3R)-3-[[5-iodo-6-methoxy-2-(morpholin-4-yl)pyrimidin-4-yl]amino]piperidine-1-carboxylate (100.0 mg, 0.19 mmol, 1.00 equiv), cesium carbonate (0.38 g, 6.00 equiv), Pd(PPh3)4 (39.3 mg, 0.034 mmol, 0.18 equiv) and copper iodide (6.5 mg, 0.034 mmol, 0.18 equiv) in DMF (5.0 mL). The crude product was purified by flash chromatography on a silica gel column eluting with ethyl acetate/petroleum ether (1:15-1:1) to provide the title compound as a white solid. MS m/z [M+H]+ (ESI): 570.
Workup
- customThe crude product was purified by flash chromatography on a silica gel column
- washeluting with ethyl acetate/petroleum ether (1:15-1:1)
Sources & evidence
- ORD record
- ord-ae5d7eb9456c4be396a35c2010267113
- Source dataset
- uspto-grants-2015_12
- Patent number
- US09221809B2
Reaction notes
Loading…